Cytokinetics ALS drug fails


Shares of Cytokinetics (CYTK -60.1%) are set for an ugly day of trading after its lead product tirasemtiv misses its Phase 2b primary endpoint of significantly improving muscle function compared to placebo in ALS patients.

The disappointing result forces the company to consider ending the product's development. Last year the firm made a dosing error in the clinical trial when it mistakenly gave placebos to patients in the treatment arm. The foul-up delayed the trial by three months and forced it to take a $5M charge.

The company's other lead program, omecamtiv mecarbil via a partnership with Amgen, also failed a Phase 2b trial (IV formulation) last September. Amgen awaits the results of a mid-stage trial on an oral formulation before deciding to proceed or exit.

The landscape for good news looks barren.

From other sites
Comments (3)
  • Patent News
    , contributor
    Comments (1457) | Send Message
     
    The perils of investing in junky pharma stocks with bad management and make silly mistakes!
    25 Apr 2014, 09:44 AM Reply Like
  • 11137741
    , contributor
    Comments (240) | Send Message
     
    What is your thought ATHX ? I feel as you do with sme of the ery Patent type tht have failed or went up and down in the same way. They can be ht and miss for sure... Buoy, what an upside when yu hit...
    25 Apr 2014, 10:14 AM Reply Like
  • pagreen1966
    , contributor
    Comments (657) | Send Message
     
    ...And what a downside when you fail!
    25 Apr 2014, 12:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs